[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341601-105":59,"doc-detail-341601-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-membranous-nectin-4-expression-patterns-and-enfortumab-vedotin-response-in-prostate-cancer","Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","","Antibody-drug conjugates (ADCs) provide targeted cancer therapy by combining monoclonal antibody specificity with chemotherapy-like cytotoxicity. The anti-NECTIN-4 ADC enfortumab vedotin (EV) is approved for urothelial cancer and is under investigation for castration-resistant prostate cancer (CRPC), including the Phase II ENCORE trial. This study evaluates EV efficacy in prostate cancer cell lines and characterizes membranous NECTIN-4 expression in primary tumors and distant metastases, showing NECTIN-4–dependent growth inhibition and predominantly low target expression in metastatic disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-membranous-nectin-4-expression-patterns-and-enfortumab-vedotin-response-in-prostate-cancer/341601/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-membranous-nectin-4-expression-patterns-and-enfortumab-vedotin-response-in-prostate-cancer/341601.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic mechanism studied in this work?","Question",{"text":112,"@type":113},"The study focuses on antibody-drug conjugates, specifically the anti-NECTIN-4 ADC enfortumab vedotin (EV), designed to selectively target tumor cells expressing NECTIN-4 and deliver a cytotoxic payload.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did EV response relate to NECTIN-4 expression in prostate cancer cell lines?",{"text":117,"@type":113},"EV inhibited growth in NECTIN-4–expressing cell lines (22Rv1 and LNCaP), while NECTIN-4–negative PC-3 cells showed significantly less responsiveness, indicating dependence on target expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What did immunohistochemistry show about NECTIN-4 in primary tumors and metastases?",{"text":121,"@type":113},"Moderate membranous NECTIN-4 expression was found only in a small subgroup of CRPC patients with lung and peritoneal metastases, whereas 100% of primary tumors and a large majority of common metastatic sites were NECTIN-4 negative.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341601,1790197807,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1111/jcmm.18572  \nOR I G I NAL ART I C L E  \nExploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer  \nRichard Weiten1,2  | Marit Bernhardt3 | Max Niemann1 | Glen Kristiansen3 | Viktor Grünwald4 | Manuel Ritter1 | Michael Hölzel5  | Markus Eckstein6  | Abdullah Alajati1 | Niklas Klümper1,5  | Philipp Krausewitz1  \n1Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany  \n2Department of Urology Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany  \n3 Institute of Pathology, University Hospital Bonn, Bonn, Germany  \n4Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany 5Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany 6Institute of Pathology, University Hospital Erlangen, Friedrich-AlexanderUniversität Erlangen-Nürnberg, Erlangen, Germany  \nCorrespondence  \nRichard Weiten, Department of Urology Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany.  \nEmail: [richard.weiten@uk-koeln.de](richard.weiten@uk-koeln.de)  \nAbstract  \nAntibody-drug conjugates (ADCs) represent a novel type of targeted cancer therapy combining the specificity of monoclonal antibodies with the cytotoxicity of conventional chemotherapy. Recently, ADCs have demonstrated practice-changing efficacy across diverse solid cancers. The anti-NECTIN-4 ADC enfortumab vedotin (EV) has just been approved for patients with urothelial cancer and is currently under investigation for patients with castration-resistant prostate cancer (CRPC e.g. Phase II ENCORE trial) . Our objective was to evaluate the efficacy of EV in established prostate cancer (PCa) cell lines and to examine the membranous NECTIN-4 expression in primary tumours (PRIM) and distant metastases (MET) . NECTIN-4 was heterogeneously expressed in the panel of PCa cell lines. EV led to growth inhibition in NECTIN-4 expressing PCa cells (22Rv1 and LNCaP), whereas the NECTIN-4-negative PC-3 cells were significantly less responsive to EV, emphasizing the dependence of EV response on its target expression. Immunohistochemical staining revealed moderate membranous NECTIN-4 expression only in a small subgroup of CRPC patients with lung and peritoneal MET [n = 3/22 with H-score ≥100, median H-score 140 (IQR 130–150)], while 100% of PRIM (n = 48/48) and 86.4% of common MET sites (n = 19/22), including lymph node, bone and liver MET, were NECTIN-4 negative. In summary, EV maybe effective in NECTIN-4-positive PCa. However, our findings demonstrate that the tumoural NECTIN-4 expression is predominantly low in metastatic PCa, which suggests that EV may only be effective in a biomarker-stratified subgroup.  \nK E Y WO R D S  \nantibody-drug conjugates, enfortumab vedotin, mCRPC, NECTIN-4, prostate cancer  \n1 | INTRODUCTION  \nPatients with metastatic prostate cancer (mPCa) face a clinical challenge, characterized by limited therapeutic alternatives and a  \nworsened prognosis.1 Overall survival (OS) is intricately tied to the locations of metastatic lesions, with lung and liver metastases exhibiting heightened lethality compared to bone and non-visceral involvement.2  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s) . Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.  \nJ Cell Mol Med. 2024;28:e18572 .  \n[https://doi.org/10.1111/jcmm.18572](https://doi.org/10.1111/jcmm.18572)  \n[wileyonlinelibrary.com/journal/jcmm](wileyonlinelibrary.com/journal/jcmm)  \n1 of 7  \nDespite promising novel anti-androgenic ther","cbCaibDBxDdhjQwy","https://ap.wps.com/l/cbCaibDBxDdhjQwy","pdf",3277452,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main therapeutic mechanism studied in this work?\",\"answer\":\"The study focuses on antibody-drug conjugates, specifically the anti-NECTIN-4 ADC enfortumab vedotin (EV), designed to selectively target tumor cells expressing NECTIN-4 and deliver a cytotoxic payload.\"},{\"question\":\"How did EV response relate to NECTIN-4 expression in prostate cancer cell lines?\",\"answer\":\"EV inhibited growth in NECTIN-4–expressing cell lines (22Rv1 and LNCaP), while NECTIN-4–negative PC-3 cells showed significantly less responsiveness, indicating dependence on target expression.\"},{\"question\":\"What did immunohistochemistry show about NECTIN-4 in primary tumors and metastases?\",\"answer\":\"Moderate membranous NECTIN-4 expression was found only in a small subgroup of CRPC patients with lung and peritoneal metastases, whereas 100% of primary tumors and a large majority of common metastatic sites were NECTIN-4 negative.\"}]","Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer | PDF",1790042758,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2ba3e030d1ac702c0fc586620794bd5.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44b7939653741fb9d46b0014554e192c.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d48c2121e42da90242e3a2c5c75fe87e.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5544f1583d577cb716344bb0485f3583.webp",980,1287]